Key Highlights

  • AOTI rose 3.85% on 21 October 2026.
  • First-half 2026 revenue rose 10% to US$35 million, with underlying growth of 18% excluding Arizona.
  • A proposed Medicare local coverage determination for topical oxygen therapy was published.
  • Final Medicare coverage could greatly expand the US addressable market.
  • Cash was about US$13.8 million at 30 June 2026.
  • Reimbursement and regulatory timing remain key risks.

AOTI, Inc. (LSE:AOTI) is a US medical technology group focused on healing chronic wounds and preventing amputations through its TWO2 topical wound oxygen therapy. The 3.85% gain on 21 October 2026 reflects continued interest in the potential expansion of Medicare coverage, although final approval and implementation timing remain uncertain.

Why Did AOTI, Inc. (LSE:AOTI) Rise by 3.85% on 21 October 2026?

The 3.85% rise reflects positive price movement, but no company announcement on 21 October 2026 was identified that explains it.

In July, AOTI reported first-half revenue up 10% to US$35 million, with underlying growth of 18% excluding Arizona Medicaid. Veterans Affairs sales and Medicaid revenue outside Arizona both increased.

The company highlighted the publication of a proposed Medicare local coverage determination for topical oxygen therapy, describing it as transformational. Finalisation would mandate Medicare coverage and reimbursement.

Healthcare technology stocks exposed to US reimbursement often react to regulatory milestones, and investors may be anticipating progress on the Medicare coverage process.

The business model of AOTI, Inc.

AOTI earns revenue by providing TWO2 therapy devices and services to patients with chronic wounds, particularly diabetic foot ulcers.

Customers include the US Veterans Affairs system, Medicaid programmes and commercial insurers.

The therapy can be administered at home, improving compliance and access.

TWO2 has regulatory clearances in the US, Europe, the UK, Canada, China, Australia and Saudi Arabia.

Revenue growth depends on prescribing clinicians, patient referrals and reimbursement approvals from payers.

Major Reasons Behind Upside

Medicare coverage is the main support. If finalised, it could expand the addressable US market substantially.

Clinical evidence shows significant reductions in hospitalisations and amputations, supporting adoption.

Underlying growth of 18% excluding Arizona shows demand in core channels.

Positive coverage guidance from health authorities in Germany and the UK support international expansion.

Real-world evidence studies published in 2026 add to the clinical data supporting TWO2 therapy.

What Are the Major Risks Investors Should Consider?

Timing of Medicare finalisation and implementation is uncertain.

Reimbursement changes could affect pricing.

The decision to stop treating new Arizona Medicaid patients reduced revenue.

Scaling sales and operations to meet demand requires investment.

Medicare coverage could also increase competition if other topical oxygen therapies seek to benefit from reimbursement.

What Is the Dividend Outlook?

AOTI does not pay dividends and is focused on growth.

Distributions are unlikely in the near term.

Cash is likely to be directed towards sales expansion and working capital if Medicare demand materialises.

How Does AOTI, Inc. Compare With Other Industry Peers?

AOTI competes with other advanced wound care providers, including negative pressure therapy and dressings.

Its differentiation is the only intermittent topical oxygen wound therapy, supported by clinical data. Larger peers have broader portfolios.

Relative performance should be judged through revenue growth, reimbursement coverage and margins.

Home-based treatment aligns with a wider shift in US healthcare towards care delivered outside hospitals, which may favour AOTI’s model.

What Are the Bull and Bear Cases for LSE:AOTI?

Bull Case:

  • Medicare coverage could transform growth.
  • Clinical outcomes could drive adoption.
  • International approvals could expand markets.

Bear Case:

  • Delays in coverage could slow growth.
  • Reimbursement pressure could reduce margins.
  • Execution challenges could limit scaling.

Technical Levels to Watch

  • Support Zone: Watch whether the shares stay above levels reached after the July update.
  • Resistance Levels: Highs from 2026 represent resistance.
  • Volume Trends: Volume around regulatory news is important.
  • Momentum Indicators: Monitor relative strength and moving averages.

What Does the ESG Investment Case Look Like?

Environmental impact is limited, relating to device manufacturing and logistics.

Social benefits include reducing amputations and hospitalisations for patients with chronic wounds.

Governance focus includes reimbursement compliance and US corporate structure.

Access to home-based therapy can reduce the burden on patients who struggle to attend clinics regularly, particularly veterans and those in rural areas.

Outlook

AOTI’s outlook depends heavily on Medicare coverage finalisation.

Investors should monitor regulatory progress, revenue growth and cash.

If Medicare coverage is finalised, the company will need to scale its sales force, logistics and billing capabilities quickly, so execution will be as important as the regulatory outcome itself.